Targovax to present at the H.C. Wainwright Virtual BioConnect 2021 Conference
Oslo, 11 January 2021 – Targovax ASA, a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, has been invited to present at H.C. Wainwright’s BioConnect 2021 Conference, being held virtually on January 11-14, 2021Øystein Soug, CEO of Targovax, will hold a company presentation to conference attendees. The recording will be available on-demand via the H.C. Wainwright conference portal. A PDF of the presentation will be available in the Investor Relations section at www.targovax.com.